---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-26-006343"
form_type: "8-K"
ticker: "ASBP"
cik: "0001847345"
company_name: "Aspire Biopharma Holdings, Inc."
filed_at: "2026-02-12T23:59:59+00:00"
generated_at: "2026-05-16T03:06:15.694456+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# Aspire Biopharma raises up to $21M via convertible preferred stock; board adds Balatsos

## Summary
- Initial closing of 13,750 Series A Convertible Preferred Shares for $11M gross proceeds; up to $21M total available.
- Preferred shares convertible into common at 80% of lowest 5-day VWAP prior to conversion, subject to 4.99% ownership cap.
- Company expects to regain Nasdaq stockholders' equity compliance (min $2.5M) after the offering.
- Donald G. Fell resigned from board; Philip Balatsos appointed to fill vacancy.
- RBW Capital Partners acted as placement agent; proceeds to support operations and reduce legacy debt.

## SEC filing metadata
- accession: 0001493152-26-006343
- form_type: 8-K
- ticker: ASBP
- cik: 0001847345
- company_name: Aspire Biopharma Holdings, Inc.
- filed_at: 2026-02-12T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 1.01, 3.02, 8.01, 5.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1847345/000149315226006343/0001493152-26-006343-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1847345/000149315226006343/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-26-006343
- JSON: https://secwatch.observer/filing/0001493152-26-006343.json
- Plain text: https://secwatch.observer/filing/0001493152-26-006343.txt

## Key facts
- Equity Issuances
  Aspire Biopharma Holdings, Inc. issued up to 25,000 shares of preferred stock to certain accredited investors for $11,000,000 aggregate gross proceeds.
  - Security: preferred stock
  - Shares: up to 25,000 shares
  - Purchaser: certain accredited investors
  - Consideration: $11,000,000 aggregate gross proceeds
  source text: Rule 5636(d) (“ Shareholder Approval ”). Pursuant to the Securities Purchase Agreement, the Company closed on an aggregate of 13,750 Shares resulting in gross proceeds of $11,000,000 including the conversion of $943,801 in existing debt into Shares on the same terms, before deducting fees to be paid to the placement agents and financial advisors of the Company
  evidence_url: https://www.sec.gov/Archives/edgar/data/1847345/000149315226006343/0001493152-26-006343-index.htm
- Material Agreements
  Aspire Biopharma Holdings, Inc. entered into Securities Purchase Agreement with certain accredited investors valued at $11,000,000 (effective 2026-02-06).
  - Action: entry
  - Agreement: equity purchase
  - Counterparty: certain accredited investors
  - Value: $11,000,000
  - Effective: 2026-02-06
  source text: On February 6, 2026, Aspire Biopharma Holdings, Inc. (the “ Company ”) entered into a securities purchase agreement (the “ Securities Purchase Agreement ”) with certain accredited investors
  evidence_url: https://www.sec.gov/Archives/edgar/data/1847345/000149315226006343/0001493152-26-006343-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.